Cancer

Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell

BURLINGAME, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, is deeply saddened to…

2 months ago

Cosmos Health Completes Acquisition of Cloudscreen, a Cutting-Edge AI Platform; Enters Lucrative $25Bn+ Global Drug Repurposing Market

CHICAGO, IL / ACCESSWIRE / January 23, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,…

2 months ago

Gilead Sciences: Art Captures the Experiences of Women Living With Metastatic Breast Cancer

NORTHAMPTON, MA / ACCESSWIRE / January 23, 2024 / For the past 30 years, Pilar Fernandez has navigated living with…

2 months ago

AngioDynamics Announces FDA 510(k) Clearance of Auryon XL Radial Access Catheter to Treat Peripheral Arterial Disease

225-cm Catheter Length Expands Access Points in Atherectomy Procedures to Help Reduce Access Site Complications and Accelerate Patient RecoveryLATHAM, N.Y.--(BUSINESS…

2 months ago

Genomate Health Adds Intelligene Healthcare as India Distributor

Genomate Health Inc, a global leader in precision oncology, announces its strategic partnership with Intelligene Healthcare Pvt Ltd, marking a…

2 months ago

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology

- University of Utah Hospital, Lori Gawron, M.D. of the Obstetrics and Gynecology (OB/GYN) Department, was an instrumental investigator in…

2 months ago

Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12’s Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy

SOLANA BEACH, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling…

2 months ago

MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs

Imugene using MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support azer-cel – a potential first-in-class allogeneic CD19 CAR T…

2 months ago

NAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber’s Hereditary Optic Neuropathy (LHON)

NAYA to accelerate Phase II clinical development and Early Patient Access after initial safety demonstrated in 28-patient clinical trialProgram developed…

2 months ago

ASTCT, AACI, and ACCC Launch RECUR Initiative to Enhance Patient Access to CAR T Therapy

CHICAGO, IL / ACCESSWIRE / January 22, 2024 / The American Society for Transplantation and Cellular Therapy (ASTCT), the Association…

2 months ago